Crisis of Confidence: Novartis Faces Investor Backlash Following String of Clinical Setbacks

Novartis, the Swiss pharmaceutical titan, is currently grappling with more than just the $30 billion evaporation of its market capitalization following a disastrous week for its R&D pipeline. The company is facing an intensifying wave of public scrutiny from top-tier institutional investors who are openly questioning the efficacy of the firm’s aggressive business development strategy and the oversight provided by its board of directors.

The catalyst for this turmoil was the failure of delpacibart etedesiran (del-desiran), a high-profile neuromuscular candidate inherited in Novartis’ $12 billion acquisition of Avidity Biosciences. The drug, which was once heralded as a potential blockbuster, failed to meet its primary endpoint in a pivotal Phase III clinical trial, triggering a massive selloff of the company’s shares and reigniting a debate over whether the pharmaceutical giant is overpaying for unproven, high-risk assets.

The Anatomy of the Failure: The HARBOR Trial

The core of the crisis lies in the HARBOR clinical trial (NCT06411288), which was designed to evaluate the efficacy of del-desiran in patients suffering from myotonic dystrophy type 1 (DM1). The study sought to prove a statistically significant improvement in video Hand Opening Time (vHOT) compared to a placebo over a 54-week period.

Del-desiran, an Antibody Oligonucleotide Conjugate (AOC), was designed to address the genetic root of DM1. By utilizing a muscle-targeting monoclonal antibody that binds to the transferrin receptor 1 (TfR1), the drug was intended to deliver a small interfering RNA (siRNA) payload to degrade the toxic myotonic dystrophy protein kinase (DMPK) mRNA. Despite receiving Orphan Drug, Fast Track, and Breakthrough Therapy designations from the FDA, the therapy failed to clear the primary hurdle of the HARBOR trial, casting significant doubt on the future of this particular drug candidate and the broader AOC platform.

A Chronology of September’s “Triple Hit”

The failure of del-desiran was not an isolated incident; it was the final blow in a devastating week for Novartis’ clinical portfolio.

• September 2, 2026: Novartis announced a pause in eight ongoing clinical trials assessing its personalized CD19-directed CAR-T therapy, rapcabtagene autoleucel (rap-cel). The decision followed the tragic deaths of three patients who developed immune effector cell-associated hemophagocytic syndrome, a severe adverse reaction that has forced a complete safety review of the program.
• September 4, 2026: Novartis and its partner, Ionis Pharmaceuticals, confirmed that their co-developed cardiovascular drug, pelacarsen, failed to meet its primary endpoint in the Phase III Lp(a)HORIZON trial. The drug failed to show a significant reduction in major adverse cardiovascular events compared to a placebo, a major setback for the company’s efforts to capture a significant portion of the high-risk heart disease market.
• September 8, 2026: The announcement regarding the HARBOR trial failure served as the crescendo of this sequence. The news prompted the worst one-day selloff of Novartis shares since the onset of the global COVID-19 pandemic in March 2020.

Investor Dissent: The "Party is Over"

The financial community’s reaction was swift and unforgiving. M. David Samra, managing director at Artisan Partners and a founding partner of the International Value Group, became the public face of the investor revolt. In a candid interview with Reuters, Samra did not mince words regarding the company’s leadership.

"I think [Chairman Giovanni Caforio] needs to make changes at the board level. One of them should be on improving the team that’s doing these deals because clearly they have been uninspiring at best," Samra stated. "The party is over. The acquisition track record is not very good."

Artisan Partners, which held a significant position in Novartis—accounting for 3.6% of its International Value Fund’s portfolio as of mid-2026—has specifically targeted the $12 billion Avidity acquisition as emblematic of a broader strategic failure. Samra argued that when a $12 billion deal yields results that approach zero, the management team must face accountability.

This sentiment has rippled through the investor base. Gillian Hollenstein of Point Capital Navigator Fund noted that "it’s going to take a while for confidence to return," while suggesting that Novartis’ strategy of "trying to hit it out of the park" with massive acquisitions is fundamentally flawed. She argued that the company would have been better served by a series of smaller, "bolt-on" acquisitions.

Supporting Data: Acquisitions and Pipeline Performance

Since 2023, Novartis has engaged in 11 significant biopharma acquisitions, with total potential deal values reaching $32.9 billion. The Avidity deal remains the most controversial due to the recent HARBOR trial results. However, the scrutiny extends to other recent purchases, including the €2.7 billion ($3.1 billion) acquisition of MorphoSys.

While Novartis maintains that the MorphoSys acquisition is intended to bolster its oncology pipeline, the path forward for the myelofibrosis candidate, pelabresib, has been far from smooth. Although the combination of pelabresib and ruxolitinib met its primary endpoint in the MANIFEST-2 trial, Novartis delayed the regulatory filing, citing the need for additional analysis of 48-week data. The company has since launched a follow-up trial, MANIFEST-3, with an estimated completion date in 2028, further delaying the potential revenue contribution from this asset.

Despite these setbacks, the company retains other assets from the Avidity acquisition that have yet to complete their trials. Del-zota (for Duchenne muscular dystrophy) is in a Phase II extension study, and del-brax (for FSHD) showed promising biomarker data in Phase I/II trials earlier this year. Whether these assets can survive the current climate of skepticism remains to be seen.

Implications for the Competitive Landscape

The clinical failure of del-desiran has fundamentally altered the competitive landscape for DM1 therapies. Analysts at William Blair, led by Myles R. Minter, PhD, have identified the opening as a strategic opportunity for competitors.

Vertex Pharmaceuticals and its partner, Entrada Therapeutics, have emerged as the primary beneficiaries of this shift. Their candidate, VX-670, which utilizes an endosomal escape vehicle (EEV) platform, is now viewed with increased optimism by market watchers. Minter pointed to the "impressive safety profile" of the EEV platform as a critical advantage, suggesting that Entrada’s approach may be better suited for the higher dosing regimens required to achieve significant muscle tissue penetration.

Financial Revisions and Future Outlook

The direct consequence of the HARBOR trial failure is a significant downward revision of peak sales forecasts. Stefan Schneider, PhD, of Vontobel Asset Management, has removed the firm’s $3 billion peak annual sales projection for del-desiran from its valuation models and subsequently lowered the Novartis price target. Similarly, Michael Schmidt, PhD, of Guggenheim, slashed the firm’s risk-adjusted 2033 sales forecast for the drug by 45%, reducing it to $960 million.

Despite the pressure, Novartis leadership remains committed to its long-term financial guidance. The company continues to forecast net sales growth at a compound annual rate of 5% to 6% through 2030. CEO Vas Narasimhan, who has overseen a 60% increase in share value during his tenure since 2018, appears to retain the support of some institutional investors who view the current volatility as "normal probabilities of drug development success."

However, the "trust issue" described by Daniel Bolanowski of Arctic Asset Management persists. The company now finds itself at a crossroads: it must either prove that its recent string of acquisitions will eventually bear fruit through its remaining pipeline, or it must fundamentally overhaul its business development strategy to satisfy a skeptical and increasingly vocal shareholder base.

As Novartis navigates this period of instability, the pharmaceutical industry will be watching closely. The outcome of the remaining Avidity-derived programs and the company’s ability to defend its current strategy against further activist pressure will define the next chapter of the Swiss giant’s history. For now, the "party" is indeed over, and the focus has shifted to the hard, often unforgiving, reality of clinical validation and fiscal discipline.